MiniMed Group, Inc.

MMED Healthcare Medical Instruments & Supplies

MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.

18.23 1.06 −5.50%
Market cap
$5.1B
P/E
0.0×
Fwd P/E
27.8×
Dividend yield
—
F-score
n/a
Altman Z
2.53
Beneish M
−3.09
Dividend safety
n/a

MiniMed Group, Inc. (MMED) EV/EBITDA

Alert me on EV/EBITDA

MiniMed Group, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2026 0.0× —
FY2025 0.0× —
FY2024 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Jul 2026 0.0× —
Jan 2026 0.0× —
Jul 2025 0.0× —
Jan 2025 0.0× —

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

EV/EBITDA against peers

Company EV/EBITDA
PLSE Pulse Biosciences, Inc compare n/m
MMED MiniMed Group, Inc. n/m
NVST Envista Holdings Corporation compare 10.3×
STVN Stevanato Group S.p.A. compare 11.3×
BLCO Bausch + Lomb Corporation compare 14.6×
MMSI Merit Medical Systems, Inc. compare 15.5×
ICUI ICU Medical, Inc. compare 16.0×
TFX Teleflex Incorporated compare 35.7×
ATRC AtriCure, Inc. compare 83.7×
Medical Instruments & Supplies industry median 14.9×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on MMED